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HBGl

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccacaaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac
ccctgaggtgcaggcttcctggcagaagatggtgactgcagtggccagtgccctgtcctccagataccactgagctcactgccc
atgattcagagctttcaaggataggctttattctgcaagcaatacaaataataaatctattctgctgagagatcac

Figure 1
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HBG2

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcaccmgcccagctgagtgaactgcactgtgac
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgmtggcaatccatttcggcaaagaattcac
ccctgaggtgcaggcttcctggcagaagatggtgactggagtggccagtgccctgtcctccagataccactgagctcactgccc
atgatgcagagcmcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac

Figure 2
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HBGln

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttcmgacagcmggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccacaaagcacctggatgattcagagcmcaaggataggcmattctgcaagcaatacaaat
aataaatctattctgctgagagatcac

Sequence ID 1

Figure 3
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HBG2n

acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgagct
cactgcccatgatgcagagctttcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac

Sequence ID 2

Figure 4
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S15

ggcagtctcgcgataactgcgcaggcgcggaccaaagcgatctcttctgaggatccggcaagatggcagaagtagagcagaa
gaagaagcggaccttccgcaagttcacctaccgcggcgtggacctcgaccagctgctggacatgtcctacgagcagctgatgc
agctgtacagtgcgcgccagcggcggcggctgaaccggggcctgcggcggaagcagcactccctgctgaagcgcctgcgc
aaggccaagaaggaggcgccgcccatggagaagccggaagtggtgaagacgcacctgcgggacatgatcatcctacccga
gatggtgggcagcatggtgggcgtctacaacggcaagaccttcaaccaggtggagatcaagcccgagatgatcggccactac
ctgggcgagttctccatcacctacaagcccgtaaagcatggccggcccggcatcggggccacccactcctcccgcttcatccct
ctcaagtaatggctcagctaataaaggcgcacatgactcc

Sequence ID 3

Figure 5
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F 5' gaa-agc-tct-gaa-tca-tcc-agg-tg 3'
Sequence ID 4

Figure 6
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6FAM-ttt-gtg-gca-tct-ccc-aag-gaa-gtc-agc MGBNFQ

Sequence ID 5

Figure 7
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R 5' agt-caa-ggc-aca-tgg-caa-gaa-g 3'

Sequence ID 6

Figure 8
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F 5' gca-gtg-agc-tca-gtg-cag-ttc 3'

Sequence ID 7

Figure 9
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6FAM-caa-agg. .tgc-cct-tga-gat-cat-cca-gg MGBNFQ

Sequence ID 8

Figure 10
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R 5' ttc-ctt-ggg-aga-tgc-cat-aaa 3'

Sequence ID 9

Figure 11
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F 5' cca-aag-cga-tct-ctt-ctg-agg-at 3

Sequence ID 10

Figure 12
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VIC-cgg-caa-gat-ggc-aga-agt-aga-gca-gaa MGBNFQ

Sequence ID 11

Figure 13
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R 5' acg-ccg-cgg-tag-gtg-aa

Sequence ID 12

Figure 14
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AGE DETERMINATION FROM BIOLOGICAL
STAINS USING MESSENGER RNA
PROFILING ANALYSIS

gations. Currently no reliable validated molecular tests are
available for age determination.
Numerous molecular theories have been investigated for
their correlation with human ageing. Postulated molecular
mechanisms include, inter alia, progressive damage to DNA,
telomere shortening, long-lived protein glycation and reactive oxygen species (ROS)-mediated oxidative damage to
macromolecules. A major downfall to these approaches is
that they are characterized by the "degenerative" ageing process, whereby as individuals increase in age the amount of
damage also increases, this is especially characteristic of
older aged individuals. From the forensic standpoint, however, it would be useful to be able to distinguish between
individuals of all age groups and this may require the detecti on of more subtle molecular changes. An alternate approach
to age determination relies on epigenetic and developmental
control of gene expression through messenger RNA (mRNA)
profiling analysis. This theory of "developmental" ageing,
would allow individuals to be categorized into various age
groups, each correlated with a specific stage of human development.
The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds through
these developmental stages, sub-sets of the 20-50 thousand
human genes will be differentially expressed. Determining
the global gene expression profile (or differential mRNA
gene expression profile) present in a biological stain could
reveal constellations of genes whose expression is correlated
with a specific age. For example, identifying fetal hemoglobin (HBG) and fetal specific regulating mRNA species, isolating pubertal and pre-pubertal hormones and receptors or
assaying for DNA damage and repair factors would be indicative of newborn babies, adolescent teenagers and elderly individuals, respectively.

This is a Divisional of application Ser. No. 11/232,313 filed
Sep. 21, 2005 now U.S. Pat. No. 7,276,340 and claims the
benefit of priority from U.S. Provisional Application Ser. No.
60/612,233 filed Sep. 22, 2004 the content of which is incorporated herein by reference.
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FIELD OF THE INVENTION
This invention relates to a ribonucleic acid (RNA) based
assay system for determining the biological age of an individual from which a body fluid originated.

15

SEQUENCE LISTING
Appendix A is a sequence listing of mRNA and DNA
sequences identified in FIGS. 1-14, the content of Appendix
A is also submitted on a compact disc and is incorporated
herein by reference. Attached hereto is one compact disc
containing the following files:
SEQ. 1 provides the mRNA sequence ofHBGl
SEQ. 2 provides the mRNA sequence ofHBG2
SEQ. 3 provides the mRNA sequence ofHBGln (Seq. ID
1)
SEQ. 4 provides the mRNA sequence ofHBG2n (Seq. ID
2)
SEQ. 5 provides the mRNA sequence of S15 (Seq. ID 3)
SEQ. 6 provides the DNA sequence of an HBG ln primer
(Seq. ID 4)
SEQ. 7 provides the DNA sequences of an HBGln probe
(Seq. ID 5)
SEQ. 8 provides the DNA sequences of an HBG ln primer
(Seq. ID 6)
SEQ. 9 provides the DNA sequences of an HBG2n primer
(Seq. ID 7)
SEQ. 10 provides the DNA sequences of an HBG2n probe
(Seq. ID 8)
SEQ. 11 provides the DNA sequences of an HBG2n primer
(Seq. ID 9)
SEQ. 12 provides the DNA sequences of an S15 primer
(Seq. ID 10)
SEQ. 13 provides the DNA sequences of an S15 probe
(Seq.ID!!)
SEQ. 14 provides the DNA sequences of an S15 primer
(Seq. ID 12)

20

25

30

35

SUMMARY OF THE INVENTION
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BACKGROUND AND PRIOR ART
It is now a routine matter for forensic scientists to obtain
the genetic profile of an individual from deoxyribonucleic
acid (DNA) recovered from a biological stain deposited at a
crime scene. However, in certain instances where there is no
developed suspect as yet or there is no match with any database sample, the DNA profile per se provides no meaningful
information to investigators, with the notable exception of
gender determination. To aid in these investigations another
useful biometric that could provide important probative information is the biological age of an individual. For example, the
ability to provide investigators with information as to whether
a DNA donor is a newborn baby, an adolescent teenager or an
elderly individual could be useful in certain cases, particularly those involving young children such as kidnappings or
in providing additional intelligence during terrorist investi-
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A primary objective of the present invention is to provide
two novel newborn specific fetal hemoglobin genes.
A second objective of the present invention is to provide an
mRNA based method for identifying the newborn specific
genes present in a bloodstain.
A third objective of the present invention is to provide a kit
for the analysis of bloodstains to determine if a particular
bloodstain originated from a newborn individual.
A preferred method for identifying whether a stain contains blood of a newborn human being, includes, obtaining a
sample stain consisting of a body fluid from a human being,
extracting total ribonucleic acid (tRNA) from the sample
stain, treating the total RNA with an enzyme, initiating a
reverse-transcription (RT) reaction by treating total RNA
with random decamer primers and a reverse transcriptase
enzyme to produce cDNA, amplifying the cDNA using
HBGv-specific and HSK primers with corresponding fluorescently labeled probes, identifying the age of the donor by
determining the cycle threshold (Ct) value of a housekeeping
gene (HSK) and the Ct value of the HBGv target gene, then
subtracting the Ct value of the target gene, from the Ct value
of the HSK gene, wherein a positive value would indicate that
the blood originates from a newborn human being.
A more preferred method uses the reverse transcriptase
enzyme, Moloney Murine Leukemia Virus (MMLV-RT) and
has 2 variants of hemoglobin (HBG) used as primers. The 2
variants ofHBG are HBG ln and HBG2n and the primers are
segments ofHBG ln and HBG2n. More preferably, the primers are one or more selected from the sequence ID 4, 5, 6, 7,
8, 9, 10, 11or12.

US 7,704,693 Bl
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The preferred identifying probes fluoresce and the values
are determined by finding the Ct of the HSK and the Ct of each
of the variants of HBG and then subtracting the Ct of the
HBGv from the Ct of the HSK, generating a dCt value. The
HSKis the ribosomal protein, S15 and the age of the newborn
is less than 1 week old or the age of the newborn can be less
than 5 months old. More preferably, the HSK is glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The preferred extracting procedure for the total RNA uses
a denaturing solution such as guanidine isothiocyanate-phenol:chloroform. Preferably, the extracted total RNA is precipitated with an organic solvent, such as, isopropanol. The
preferred enzyme used to treat the extracted total RNA is
deoxyribonuclease I (DNase I).
A preferred gene coding for the human newborn specific
fetal hemoglobin variant is HBGln as in SEQ ID 1 and
HBG2n as in SEQ ID 2.
Another preferred gene coding for the human newborn
specific fetal hemoglobin variants are HBGln and HBG2n
and polymorphisms thereof.
A preferred kit for use in determining the biological age of
an individual in an unknown bloodstain, uses HBGln and
HBG2n and HSK specific primers, preferably, selected from
one or more of sequence ID 4, 5, 6, 7, 8, 9, 10, 11, or 12; the
preferred housekeeping gene is the ribosomal protein, S15.
The preferred probes are labeled with fluorescent dyes.
Further objects and advantages of this invention will be
apparent from the following detailed description and example
of a presently preferred embodiment.

The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds through
these developmental stages, sub-sets of the 20-50 thousand
human genes will be differentially expressed. Determining
the global gene expression profile (or differential mRNA
gene expression profile) present in a biological stain could
reveal constellations of genes whose expression is correlated
with a specific age. For example, identifying fetal hemoglobin and fetal specific regulating mRNA species, isolating
pubertal and pre-pubetal hormones and receptors or assaying
for DNA damage and repair factors, would be indicative of
newborn babies, adolescent teenagers and elderly individuals, respectively.
A clear example of age related differential gene expression
involves the fetal to adult hemoglobin shift. The human betahemoglobin locus is located on the short arm of chromosome
11 (llp15.5), and encodes five functional beta-like globin
genes: epsilon, gammaG, ganimaA, delta, and beta, (hemoglobin ganima mRNA sequences, HBGl (ganimaA) and
HBG2 (gammaG), are provided in FIG. 1 and FIG. 2, respectively).
The expression of embryonic hemoglobin (epsilon) commences in the yolk sac in the early stages of gestational
development. During the fifth week of gestation the fetal liver,
spleen and bone marrow begin to express the fetal specific
gamma hemoglobin chains (ganimaA and gammaG) to form
the fetal hemoglobin protein. This up-regulation of gammaglobin is accompanied by a shutdown of epsilon-globin synthesis. Shortly before birth, beta-globin gene expressioncommences in the bone marrow, forming adult hemoglobin and
inturn ganima-globin expression is down regulated. Therefore, the development of an assay which identifies ganima
hemoglobin mRNA in a biological stain, would indicate that
the donor of the stain is a newborn baby.
The gamma hemoglobin locus was analyzed by reverse
transcription-polymerase chain reaction (RT-PCR) using two
sets of highly specific primers, one designed to specifically
amplify HBG 1 (gammaA) and one designed for amplification
of HBG2 (gammaG). In contrast to our initial hypothesis, a
messenger RNA (mRNA) product corresponding to the individual HBG 1 or HBG2 genes was amplified in all age groups
tested. These results demonstrated that the production of
gamma hemoglobin mRNA is not restricted to the fetal and
newborn stages of development. Upon further investigation
of these RT-PCR assays, the presence of an additional lower
molecular weight amplimer was detected in only newborn
individuals. These lower molecular weight products were
excised, cloned, sequenced and aligned with the standard
hemoglobin genes. Alignment analysis revealed these lower
molecular weight amplimers to be variants of the standard
gamma hemoglobin genes (HBGv) which we have termed
HBGln and HBG2n (variant ganima hemoglobin mRNA
sequences HBGln and HBG2n are provided in FIG. 3 and
FIG. 4, respectively).
Based on this process the invention provides real-time PCR
duplexes which are composed of one novel newborn specific
fetal hemoglobin variant, HBGln or HBG2n, whose
sequences are identified as SEQUENCE ID 1 (HBG ln) (FIG.
3), SEQUENCE ID 2 (HBG2n) (FIG. 4), and one housekeeping gene (HSK), which may be the ribosomal protein, S15,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
others (example ofa HSK gene sequence, S 15, (SEQUENCE
ID 3) (FIG. 5)). The collection of genes that are expressed
within the constellation of differentiated cells that make up a
body fluid is called the multicellular transcriptome. These
genes comprise ubiquitously expressed housekeeping (HSK)
genes, which are responsible for cell maintenance functions
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BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 provides the mRNA sequence ofHBGl
FIG. 2 provides the mRNA sequence ofHBG2
FIG. 3 provides the mRNA sequence ofHBGln
FIG. 4 provides the mRNA sequence ofHBG2n
FIG. 5 provides the mRNA sequence ofS15
FIG. 6 provides the DNA sequence of an HBG ln primer
FIG. 7 provides the DNA sequences of an HBG ln probe
FIG. 8 provides the DNA sequences of an HBG ln primer
FIG. 9 provides the DNA sequences of an HBG2n primer
FIG. 10 provides the DNA sequences of an HBG2n probe
FIG. 11 provides the DNA sequences of an HBG2n primer
FIG.12 provides the DNA sequences of an S15 primer
FIG.13 provides the DNA sequences of an S15 probe
FIG.14 provides the DNA sequences of an S15 primer

35
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45

DESCRIPTION OF THE PREFERRED
EMBODIMENTS
50

Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
Below is a listing of several acronyms used herein:
DNA is deoxyribonucleic acid
Ct is cycle threshold value; it is the cycle number at which the
fluorescent signal passes a pre-determined threshold.
HBG is hemoglobin
HSK is housekeeping gene
RNA is ribonucleic acid
mRNA is messenger ribonucleic acid
ROS is reactive oxygen species
RT-PCR is reverse transcription polymerase chain reaction
S15 is ribosomal protein
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independent of biological age, and genes that are specifically
expressed in an age dependent manner.
Fluorescent (i.e. FAM (6-carboxyfluorescein) and VIC)
dye-labeled probes (i.e. minor groove binding non-fluorescent quencher (MGBNFQ)) and their corresponding unlabeled primers are incorporated into the real-time PCR
(qPCR) reaction. These qPCR duplexes have been optimized
to determine if a bloodstain originated from a newborn individual and are sensitive with as little as 50 pg of input RNA
(intotheqPCRreaction). Thereal-timeqPCRmethodologyis
based on determining the delta cycle threshold (dCt) values
generated using the cycle threshold (Ct) of the HSK gene and
the Ct of the novel hemoglobin variants (HBGv) (dCt=Ct
S15-Ct HBGv). A positive dCt value would indicate a newborn origin; in contrast a negative dCt value would be
obtained with all other ages.
An mRNA based approach for age determination, such as
the real time PCR assays described above, could allow the
facile identification of the newborn specific genes present in
a bloodstain and could rapidly become a validated molecular
test for newborn specific age determination.
As an example, the assay of the invention can be performed
in two fashions: one in which the newborn is identified as less
than 1 week old; the other as less than 5 months old, depending on the amount of material used.
The following example provides further explanation of the
present invention.

appropriate mRNA species. The gene-specific primers are
incorporated with fluorescently labeled probes (i.e. FAM and
VIC) into a single multiplexed quantitative polymerase chain
reaction (qPCR). The mRNA is amplified and this amplification is detected by determining the fluorescent emission of the
dye-labeled probe.

5

Example 2
10

In an assay of the invention which identifies newborns that
are from 1 hour to 1 week in biological age one may proceed
as Example 1 above using:
HBGln

15

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
HBG2n
20

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
S15
25

900 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe

Example 1

Example 3
30

For RNA isolation, total RNA is extracted from a bloodstain using a denaturing solution, composed of guanidine
isothiocyanate, the RNA is isolated with acid phenol:chloroform and precipitated with isopropanol and GlycoB!ue™
glycogen carrier (fromAmbion Inc., Austin, Tex.). The RNA
is centrifuged and the pellet is washed once with a 75%
ethanol/25% DEPC-treated water solution. The pellet is
dried, re-solubilized and stored in an RNAsecure Resuspension Solution (Ambion Inc.,Austin, Tex.). Next, the extracted
total RNA is treated with an enzyme, deoxyribonuclease I
(TURBO™ DNase (RNase-Free)) (Ambion Inc., Austin,
Tex.), quantitated using the unsymmetrical cyanine dye
RiboGreen® (Molecular Probes, Eugene, Oreg.) and then
reverse-transcribed using fifty micromolar random decamers
as the first strand primer, producing complementary DNA
(cDNA). The Moloney Murine Leukemia Virus-Reverse
Transcriptase enzyme (MMLV-RT) from Ambion Inc., Austin, Tex., was used in this case. Finally, the cDNA is amplified
using housekeeping and newborn gene-specific primers (as
exemplified in FIGS. 6-14).
Based on the above extraction and purification technique,
duplex real-time PCR assays using in this case the Taqman®
Universal PCR Master Mix in the 7000 Sequence detection
System from Applied Biosystems, Foster City, Calif., and
standard cycling conditions such as: Step 1: 1 cycle of 50
degrees C., for 2:00 minutes; Step 2: 1 cycle of95 degrees C.,
for 10:00 minutes; Step 3: 40-50 cycles of95 degrees C., for
0: 15 seconds and 60 degrees C., for 1:00 minute; wherein data
is collected at stage 3, step 2 (60 degrees C., for 1:00) were
developed which can definitively identify newborn RNA.
These duplex reactions are composed of one of the two novel
variant forms of newborn gamma hemoglobin (HBGv),
HBGln or HBG2n, and a housekeeping (HSK) gene, the
ribosomal protein, S 15 and have been optimized for the detection of newborn individuals from bloodstains. The methodology is based on gene expression profiling analysis in which
the HBGv genes are identified by detecting the presence of

In an assay of the invention which identifies newborns that
are from 1 hour to 5 months in biological age one may proceed as in Example 1 above using:
HBGln

35

100 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
HBG2n

40

50 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
S15

45

600 nanomolar of each primer (Forward and Reverse)
250 nanomolar of the probe
50

Example 4
The cycle threshold (Ct) values obtained are used to determine the delta Ct (dCt) for that particular sample. The equation for dCt calculation is:

55

Ct(S 15)-Ct(HBG ln)~dCt
Ct(S 15)-Ct(HBG2n)~dCt

60

65

If the dCt value is positive then the sample originated from
a newborn.
If the dCt value is negative then the sample originated from
an age other than newborn.
Ifno Ct value is generated with the newborn genes (HBG ln
or HBG2n) the sample is given a Ct value of 40.000 (the
maximum number of cycles), for that particular gene. If no Ct
value is generated with the housekeeping gene (Sl 5) than the
assay must be repeated.

US 7,704,693 Bl
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While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to

be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

14

SEQ ID NO 1
LENGTH, 584
TYPE, DNA
ORGANISM, HBGl

<400> SEQUENCE,

1

acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga

360

acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat

420

tcacccctga ggtgcaggct tcctggcaga agatggtgac tgcagtggcc agtgccctgt

480

cctccagata ccactgagct cactgcccat gattcagagc tttcaaggat aggctttatt

540

ctgcaagcaa tacaaataat aaatctattc tgctgagaga tcac

584

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 583
TYPE, DNA
ORGANISM, HGB2

<400> SEQUENCE,

2

acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga

360

acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat

420

tcacccctga ggtgcaggct tcctggcaga agatggtgac tggagtggcc agtgccctgt

480

cctccagata ccactgagct cactgcccat gatgcagagc tttcaaggat aggctttatt

540

ctgcaagcaa tcaaataata aatctattct gctaagagat cac

583

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 367
TYPE, DNA
ORGANISM, HBGln

<400> SEQUENCE,

3

acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180
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10
-continued

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgattcag

300

agctttcaag gataggcttt attctgcaag caatacaaat aataaatcta ttctgctgag

360

agatcac

367

<210> SEQ ID NO 4
<211> LENGTH, 421
<212> TYPE, DNA
<213> ORGANISM, HBG2n
<400>

SEQUENCE, 4

acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc

60

atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag

120

atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct

180

ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg

240

cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca

300

agggcacctt tgcccagctg agtgaactgc actgagctca ctgcccatga tgcagagctt

360

tcaaggatag gctttattct gcaagcaatc aaataataaa tctattctgc taagagatca

420

c

421

<210> SEQ ID NO 5
<211> LENGTH, 531
<212> TYPE, DNA
<213> ORGANISM, S15
<400>

SEQUENCE, 5

ggcagtctcg cgataactgc gcaggcgcgg accaaagcga tctcttctga ggatccggca

60

agatggcaga agtagagcag aagaagaagc ggaccttccg caagttcacc taccgcggcg

120

tggacctcga ccagctgctg gacatgtcct acgagcagct gatgcagctg tacagtgcgc

180

gccagcggcg gcggctgaac cggggcctgc ggcggaagca gcactccctg ctgaagcgcc

240

tgcgcaaggc caagaaggag gcgccgccca tggagaagcc ggaagtggtg aagacgcacc

300

tgcgggacat gatcatccta cccgagatgg tgggcagcat ggtgggcgtc tacaacggca

360

agaccttcaa ccaggtggag atcaagcccg agatgatcgg ccactacctg ggcgagttct

420

ccatcaccta caagcccgta aagcatggcc ggcccggcat cggggccacc cactcctccc

480

gcttcatccc tctcaagtaa tggctcagct aataaaggcg cacatgactc c

531

<210> SEQ ID NO 6
<211> LENGTH, 23
<212> TYPE, DNA
<213> ORGANISM, HBGln
<400>

SEQUENCE,

gaaagctctg aatcatccag gtg

23

<210> SEQ ID NO 7
<211> LENGTH, 27
<212> TYPE, DNA
<213> ORGANISM, HBGln
<400>

SEQUENCE, 7

tttgtggcat ctcccaagga agtcagc

27
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11
-continued
<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 22
TYPE, DNA
ORGANISM, HBGln

<400> SEQUENCE, 8
agtcaaggca catggcaaga ag

<210>
<211>
<212>
<213>

22

SEQ ID NO 9
LENGTH, 21
TYPE, DNA
ORGANISM, HBG2n

<400> SEQUENCE, 9
gcagtgagct cagtgcagtt c

<210>
<211>
<212>
<213>

21

SEQ ID NO 10
LENGTH, 26
TYPE, DNA
ORGANISM, HBG2n

<400> SEQUENCE, 10
caaaggtgcc cttgagatca tccagg

<210>
<211>
<212>
<213>

26

SEQ ID NO 11
LENGTH, 21
TYPE, DNA
ORGANISM, HBG2n

<400> SEQUENCE, 11
ttccttggga gatgccataa a

<210>
<211>
<212>
<213>

21

SEQ ID NO 12
LENGTH, 23
TYPE, DNA
ORGANISM, S15

<400> SEQUENCE, 12
ccaaagcgat ctcttctgag gat

<210>
<211>
<212>
<213>

23

SEQ ID NO 13
LENGTH, 27
TYPE, DNA
ORGANISM, S15

<400> SEQUENCE, 13
cggcaagatg gcagaagtag agcagaa

<210>
<211>
<212>
<213>

27

SEQ ID NO 14
LENGTH, 17
TYPE, DNA
ORGANISM, S15

<400> SEQUENCE, 14
acgccgcggt aggtgaa

17

We claim:
1. An isolated gene coding for the human newborn specific
fetal hemoglobin variant HBGln as in SEQ ID3.
2. An isolated gene coding for the human newborn specific
fetal hemoglobin variant HBG2n as in SEQ ID 4.

65

3. A kit for use in determining the biological age of an
individual
in an unknown bloodstain, comprising HBGln and
HBG2n and HSK specific primers and probes wherein
the primers are selected from the group consisting of one
or more of SEQ ID 6, and 9.
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4. A kit, as in claim 3, wherein said housekeeping gene is

the ribosomal protein S15.
5. A kit, as in claim 3, wherein said probes are selected from
the group consisting of one or more of Sequence ID 7 and
Sequence IDlO.
6. A kit, as in claim 3, wherein said probes are labeled with
fluorescent dyes.

14
7. An isolated forward primer for the human newborn

specific fetal hemoglobin variant HBGln as in SEQ ID 6.
8. An isolated forward primer for the human newborn
specific fetal hemoglobin variant HBG2n as in SEQ ID 9.
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